Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing.

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late last year, although full analysis of the OS has only been completed by ...

Roche (OTCQX:RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of a certain type of breast cancer with a PIK3CA mutation. The agency ...

A new blood test being developed through a collaboration between Roche Diagnostics and Eli Lilly and Co. has been granted a breakthrough device designation by the U.S. Food and Drug Administration.

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set ...

Some people with ER-positive, HER2-negative breast cancer develop changes in a gene called ESR1 after taking these medicines, which can make them less effective. As a result, the cancer may get worse.

The FDA finished its 30-day review of Hepzato with standard care in liver-dominant metastatic breast cancer. Among patients with liver-dominant metastatic breast cancer, the United States Food and ...

FDA approved a new method to screen for cervical cancer, using two self-screening tools. Hotspots ranked Start the day smarter ☀️ Funniest cap messages Get the USA TODAY app U.S. Politics ...

Drs Kathy D. Miller and Sunil S. Badve discuss the importance of identifying HER2-low patients, those with ultra-low staining, and the benefit of targeted ADCs.

Lilly, Roche to get expedited FDA review for blood test to diagnose Alzheimer’s disease. By. Staff Reports - April 17, 2024. 0. 80. Facebook. Twitter. Pinterest. WhatsApp. By John Russell .